Philogen SpA
MIL:PHIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TI Fluid Systems PLC
LSE:TIFS
|
UK |
Philogen SpA
Note Receivable
Philogen SpA
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Philogen SpA
MIL:PHIL
|
Note Receivable
€1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genenta Science SPA
NASDAQ:GNTA
|
Note Receivable
€290.2k
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Ulisse Biomed Spa
MIL:UBM
|
Note Receivable
€102.7k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Philogen SpA
Glance View
Philogen SpA engages engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 135 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The firm's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
See Also
What is Philogen SpA's Note Receivable?
Note Receivable
1.6m
EUR
Based on the financial report for Dec 31, 2024, Philogen SpA's Note Receivable amounts to 1.6m EUR.
What is Philogen SpA's Note Receivable growth rate?
Note Receivable CAGR 1Y
-42%
Over the last year, the Note Receivable growth was -42%.
